Secukinumab Significantly Reduces Work Impairment and Indirect Costs Compared To Ustekinumab and Etanercept In The United Kingdom
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.3069
https://www.valueinhealthjournal.com/article/S1098-3015(17)33404-6/fulltext
Title :
Secukinumab Significantly Reduces Work Impairment and Indirect Costs Compared To Ustekinumab and Etanercept In The United Kingdom
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33404-6&doi=10.1016/j.jval.2017.08.3069
First page :
A804
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2216